TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients \>/= 18 years of age~* Diabetes mellitus, Type 2~* Moderately impaired kidney function~* Drug naive or up to 2 antihyperglycemic medications at stable dose for over 1 month at screening~* BMI 25-35~Exclusion Criteria:~* Current or previous treatment with a thiazolidinedione~* Current or previous treatment with insulin~* Treatment with fibrates \<3 months prior to screening~* History of renal disease other than diabetic nephropathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- aleglitazar (Type: EXPERIMENTAL): None
- pioglitazone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Certoparin in Renal Patients Undergoing Hemodialysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients requiring hemodialysis~* Patients requiring anticoagulation therapy during hemodialysis~* Written informed consent~Exclusion Criteria:~* Hypersensitivity to study medication~* Genetic abnormality or disease of clotting system~* Prior major surgery or bleeding~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Certoparin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Frequent migraine (\>=15 headache days per month)~* \>=4 distinct headache episodes lasting \>=4 hours~* \>=50% of baseline headache days migraine/probable migraine days~Exclusion Criteria:~* Previous use of botulinum toxin of any serotype or immunization to any botulinum toxin serotype~* Any medical condition that puts the patient at increased risk with exposure to BOTOX~* Diagnosis of complicated migraine, chronic tension-type headache, hypnic headache, hemicrania continua, new daily persistent headache~* Use of prophylactic headache medication within 28 days prior to week -4~* Unremitting headache lasting continuously throughout the 4-week baseline period~* Known or suspected Temporomandibular Disorders (TMD)~* Diagnosis of fibromyalgia~* Beck depression inventory score \>24 at week-4~* Psychiatric problems that may have interfered with study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- botulinum toxin Type A (Type: EXPERIMENTAL): Two treatment sessions in the double-blind phase and three treatment sessions in the open-label extension phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
- Placebo (saline) (Type: PLACEBO_COMPARATOR): Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Remifentanil and Dexmedetomidine for Craniotomy Perioperative Hemodynamics and Postoperative Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients who undergo general anesthesia for elective surgical excision of a brain tumor with following specifications:~* Age: Older than 18~* Primary and redo cases will be included~* Duration of surgery not exceeding 6 hrs.~Exclusion Criteria:~* Patient refusal~* Emergency craniotomy~* Morbid obesity~* Uncontrolled hypertension - DBP more than 110~* Cardiac conduction defects~* Patients with chronic pain.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Remifentanil (Type: ACTIVE_COMPARATOR): Remifentanil 0.08-0.15MCG/KG/MIN INFUSION THROUGHOUT PROCEDURE BASED ON HEMODYNAMICS
- Dexmedetomidine (Type: ACTIVE_COMPARATOR): a loading dose of dexmedetomidine was given at 0.5 to 1 micrograms/kg ideal body weight over 15 minutes, followed by an infusion at 0.2 to 0.7 micrograms/kg/hour.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic HIV-1 infection~* Treatment with a well-tolerated combination of antiretroviral drugs unchanged for at least 3 months, including enfuvirtide~* Absence of any uncontrolled opportunistic disease~* No restrictions on CD4 lymphocyte levels~* Plasma HIV-1 RNA below 400 copies per ml for at least 3 months (at least two consecutive tests below 400 copies per ml prior to inclusion in the study, not including that on W -4)~* For women of childbearing age, use of mechanical contraception during any sexual intercourse and negative pregnancy test (plasma ß HCG) at W -4~Exclusion Criteria:~* HIV-2 infection~* Plasma HIV-1 RNA levels above 400 copies/ml on one occasion during the 3 months prior to screening (or the pre-inclusion visit at W -4)~* Poor compliance with antiretroviral therapy current at W -4~* Current treatment with an investigational drug (except cohort ATU)~* Patient previously treated with an integrase inhibitor in the context of a clinical study~* Woman who is pregnant or likely to become so, is breastfeeding or refuses to use contraception~* Multiple drug therapy ongoing or necessary in the foreseeable future for Kaposi's disease or lymphoma~* Treatment with interferon ongoing or necessary in the foreseeable future for chronic hepatitis B or C~* Acute hepatitis whatever the case, or decompensated cirrhosis~* Current treatment with interferon, interleukin or anti-HIV vaccine~* Any condition (including, but not limited to, the consumption of alcohol or drugs) which might, in the investigator's opinion, compromise the safety of treatment and/or patient compliance with the protocol~* Significant biological abnormalities (hemoglobin below 8g per dl, polynuclear neutrophils below 750 per mm3, platelets below 50,000 per mm3, serum creatinine above 3 times the level deemed normal by the laboratory (N), ASAT or ALAT above 5N, serum lipase above 2N) and total bilirubin above 2N (except if the patient is receiving atazanavir or indinavir)~* Concomitant treatments including one or more compounds interacting with UGT1A1~  * anti-infective agents: rifampicin/rifampin~ * psychotropic/anti-epileptic drugs: phenytoin, phenobarbital.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intensification arm (Type: EXPERIMENTAL): emtricitabine/TDF + efavirenz or lopinavir/ritonavir + enfuvirtide
- Standard arm (Type: ACTIVE_COMPARATOR): emtricitabine/TDF + efavirenz or lopinavir/ritonavir

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* Currently meet the DMS-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) criteria for Major Depressive Disorder (MDD)~* The participant must have an ongoing major depressive episode of at least 8 weeks and no more than 18 months~* The participant must have at least 3 lifetime episodes of MDD (including the current episode)~Exclusion Criteria:~* Women who are pregnant, women who will be breastfeeding during the study, and women with childbearing potential who are not practicing a reliable method of birth control~* Participants who are considered a suicide risk~* History of non-response to 2 or more antidepressants (after adequate treatment)~* Participants who have a history of meeting DMS-5 criteria for manic, hypomanic, or mixed episode, obsessive-compulsive disorder, schizophrenia or other psychotic disorder~* Panic disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Open-Label FETZIMA® (Type: EXPERIMENTAL): FETZIMA® (levomilnacipran extended release \[ER\]) taken orally during flexible dose titration up to 40, 80 or 120 mg once daily in 8-week run-in period followed by fixed dose of 40, 80 or 120 mg once daily in 12-week stabilization period.
- Double-Blind Placebo (Type: PLACEBO_COMPARATOR): Dose-matched placebo taken orally once daily for 26 weeks during double-blind treatment period.
- Double-Blind FETZIMA® (Type: EXPERIMENTAL): FETZIMA® (levomilnacipran ER) taken orally at fixed dose of 40, 80 or 120 mg once daily for 26 weeks during double-blind treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Enhancing Spatial Navigation Using Non-Invasive Brain Stimulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~General inclusion criteria (all participants):~* All medications stable for approximately 1-2 months;~* No history of severe mental illness;~* No current untreated alcohol or substance abuse/dependence;~* English as native and preferred language;~* MRI-compatible if taking part in fMRI studies~* Able to give informed consent.~MCI Inclusion Criteria:~* Diagnosis of amnestic MCI based on criteria set forth by Petersen (2004). Additionally, other potential causes of cognitive deficit ruled out by the referring physician;~Healthy older adults~* intact cognitive functioning as measured by neuropsychological testing~Exclusion Criteria:~* History of neurological disease or injury~* History of severe mental illness~* Current untreated alcohol or substance abuse~* Other conditions may exclude; please discuss with contact

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 88 Years
- Healthy Volunteers: t

Study Arms:
- Cognitively intact older adults - ACTIVE tDCS (Type: EXPERIMENTAL): Group receives active brain stimulation
- MCI ACTIVE tDCS (Type: ACTIVE_COMPARATOR): Group receives active brain stimulation
- Cognitively intact older adults - SHAM tDCS (Type: SHAM_COMPARATOR): Group receives sham brain stimulation
- MCI SHAM tDCS (Type: SHAM_COMPARATOR): Group receives sham brain stimulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Volume Restoration of the Aging Midface With Sculptra Aesthetic

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 40-60 years old~* BMI greater than 18.5 and less than 24.9~Exclusion Criteria:~* Age less than 40 years or greater than 60 years~* Prior surgical or non-surgical treatment to the midface within the past 2 years~* Interested in seeking other treatments to the midface during the study period~* Pregnant, lactating, or breast feeding~* Hypersensitivity to poly-L-lactic acid, carboxymethylcellulose, or mannitol~* Allergy to lidocaine or epinephrine~* History of atopy, anaphylaxis, or multiple severe allergies~* Current immunotherapy or history of autoimmune disease~* History of or active stroke or myocardial infarction~* History of or active connective tissue disease~* History of or active bleeding disorders~* History of or active cancer~* Serious abnormalities in laboratory findings~* Active hepatitis~* Active infection or inflammatory process of skin~* History of or risk factors for hypertrophic scarring or keloid formation

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Sculptra Aesthetic (Type: EXPERIMENTAL): Patients receiving Sculptra Aesthetic

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Oxytocin Administration and the Neural Correlates of Social and Non-Social Visual Perception

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults ages 18-64~* Good medical health~* Ability to understand and speak English~Exclusion Criteria:~* Pregnancy~* Medical Illnesses: Moderate or severe acute or chronic medical illnesses (e.g. cardiac disease, diabetes, epilepsy, influenza).~* Cardiovascular risk factors: History of hypertension with baseline blood pressure above 140 mm Hg (systolic) over 90 mm Hg (diastolic). Also any history of syncope and/or baseline blood pressure below 100 mm Hg (systolic).~* CNS disease: Known history of brain abnormalities (e.g., neoplasms, subarachnoid cysts), cerebrovascular disease, infectious disease (e.g., abscess), other central nervous system disease, or history of head trauma which resulted in a persistent neurologic deficit or loss of consciousness \> 3 minutes.~* Medication status: Individuals on stable doses of a neuroleptic and/or an antidepressant medication for at least the past 6 weeks will be allowed to participate in this study. The use of other psychotropic medications will not be allowed. Females taking contraceptive hormones will not be able to participate in the study.~* A history of seizures or current use of anticonvulsants; history of head injury with loss of consciousness

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Oxytocin (Type: EXPERIMENTAL): Each participant will receive both the oxytocin nasal spray in one visit AND the placebo nasal spray in another visit (randomized) in this design.
- Placebo (Type: PLACEBO_COMPARATOR): Each participant will receive both the oxytocin nasal spray in one visit AND the placebo nasal spray in another visit (randomized) in this design.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who are at least 18 years of age.~* Subjects who are candidates for routine, uncomplicated cataract surgery.~Exclusion Criteria:~* Subjects who have known hypersensitivity or contraindication to the study drug or components.~* Subjects with a severe/serious ocular condition, or any other unstable medical condition, that in the investigator's opinion may preclude study treatment or follow-up.~* Subjects with elevated intraocular pressure (\>/=21mm Hg), uncontrolled glaucoma, or being treated for glaucoma in the study eye.~* Subjects who are monocular or have pinholed Snellen visual acuity (VA) 20/200 or worse in the non-study eye.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Loteprednol etabonate (Type: EXPERIMENTAL): Loteprednol etabonate 0.5% ophthalmic suspension
- Vehicle (Type: PLACEBO_COMPARATOR): Vehicle of loteprednol etabonate ophthalmic suspension

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of Clinical Pharmacists in Epilepsy Management

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* were prescribed a monotherapy or polytherapy of phenytoin, carbamazepine, or valproic acid.~* were treated for more than one month.~Exclusion Criteria:~* were pregnant or breastfeeding women.~* had a history of alcoholism.~* had liver or renal disease.~* were using drugs known to have an influence on cytochrome P450 enzymes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with epilepsy (Type: EXPERIMENTAL): The therapies of patients with epilepsy were optimized using pharmacists' interventions, including medication consultation, dosage adjustment, medication switching/discontinuation, or combination therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of refractory epilepsy with simple or complex partial onset seizures with or without secondary generalization~* 28-day partial seizure frequency rate of four or more partial seizures over the 8-week baseline phase~* Currently treated with up to three established AEDs~* Vagal Nerve Stimulator may be included~Exclusion Criteria:~* Existing medical or psychiatric condition which could affect patient's health or compromise ability to participate in the study~* Clinically significant abnormalities on physical exam, vital signs, ECG, or liver function tests~* Impaired renal function (creatinine clearance less than 50 mL/minute)~* Evidence of progressive central nervous disease, lesion, or encephalopathy~* History of primary generalized seizures~* History of clustering or flurries or status epilepticus within 12 months of study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Retigabine 600 mg (Type: EXPERIMENTAL): None
- Retigabine 900 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* 18 to 79 years of age, inclusive~* Chronic Kidney Disease Stage 3 or Stage 4~* Hemoglobin (Hgb) \< 10.5 g/dl~* TSAT \> 20% and CBC indicating normocytic red blood cell morphology~Key Exclusion Criteria:~* BMI \> 40~* Red blood cell transfusion within 12 weeks.~* Androgen therapy within the previous 21 days prior to study dosing~* Therapy with any approved or experimental erythropoiesis stimulating agent (ESA) within the 10 weeks prior to the Screening visit~* Participants meeting the criteria of ESA resistance within the previous 4 months~* Individual doses of intravenous iron of 250 mg or larger within the past 21 days~* AST or ALT \>1.8x ULN.~* Alkaline phosphatase \>2x ULN.~* Total bilirubin \>1.5x ULN.~* Uncontrolled hypertension~* New York Heart Association Class III or IV congestive heart failure~* Myocardial infarction, acute coronary syndrome, or stroke within 6 months prior to dosing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- AKB-6548 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete